India revokes patent of Novartis’ cardiac drug – The Times of India
NEW DELHI: The Indian Patent Office (IPO) has revoked the patent on Novartis’ cardiac blockbuster drug Vymada on grounds of lack of novelty, potentially paving the way for affordable generics to enter the market.The popular therapy has been in the spotlight for years, with generic versions from Natco, Torrent Pharma, MSN Labs and Eris Lifesciences…